
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at different doses of trastuzumab (Herceptin) alongside chemotherapy for stomach cancer, or cancer where the food pipe (oesophagus) meets the stomach (gastro oesophageal junction cancer). The people taking part have cancer that has spread to at least 2 other places in the body and has large amounts of a protein called .
Doctors can use a biological therapy drug called Herceptin with chemotherapy for stomach cancer or gastro oesophageal cancer that has spread to other parts of the body. It only works for people whose cancer cells have large amounts of a protein called human epidermal growth factor receptor 2 (HER2). This is known as HER2 positive cancer.
In this trial, researchers want to see if having a higher dose of Herceptin alongside chemotherapy will help people more than the standard dose that is currently used.
The aims of the trial are to find out
You may be able to enter this trial if
You cannot enter this trial if you
This phase 3 trial will recruit about 400 people. It is a randomised trial. The people taking part are put into 1 of 2 treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in.
People in one group have the standard dose of Herceptin. People in the other group have a higher dose.
You have Herceptin and cisplatin through a drip into a vein once every 3 weeks. You take capecitabine tablets every day for 2 weeks, followed by a week without treatment. Each 3 week period is called a cycle of treatment.
After 6 cycles of treatment, you stop having cisplatin and capecitabine. But as long as you don’t have bad side effects, you can carry on having Herceptin alone for as long as it helps you.
The trial team may ask you to take part in a sub study looking at the amount of Herceptin in your blood at different times. This is called . If you agree to take part, you give a number of extra blood samples before and after each dose of Herceptin. You don’t have to take part in this study if you don’t want to. You can still take part in the main trial.
You see the trial team and have some tests before you start treatment. The tests include
The researchers will test a sample of your cancer that was removed in the past, to see if it is HER2 positive.
During treatment, you go to hospital every 3 weeks. You have
When you finish treatment, you see the trial team between 4 and 5 weeks later. You have a heart ultrasound or MUGA scan 4 times in the following 2 years.
You have a CT scan every 6 weeks until your cancer starts to grow again. During this time, the trial team will contact you by phone every 3 months to see how you are.
The side effects of Herceptin include
If you have heart problems, Herceptin can make them worse. The trial team will regularly monitor how well your heart is working.
We have more information about the side effects of cisplatin and capecitabine in our cancer drugs section.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Mano Joseph
Experimental Cancer Medicine Centre (ECMC)
Roche
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.